Can-Fite BioPharma (CANF) outlines reverse split and ADS ratio change

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. furnished a report noting that it issued a press release titled “Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change.” The company states that this press release, dated December 23, 2025, is incorporated by reference into its existing Form S-8 and Form F-3 registration statements. The report is signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer.

Insights

Equity structure and disclosure analyst

Can-Fite reports a planned reverse split and ADS ratio change.

Can-Fite BioPharma Ltd. discloses that it has announced a reverse split of its ordinary shares and a change to its American Depositary Share (ADS) ratio through a press release. These actions affect how the company’s equity is structured and how its shares trade, but specific split or ratio terms are contained in the referenced press release, not in this summary.

The company also incorporates that press release by reference into multiple existing Form S-8 and Form F-3 registration statements, linking the equity-structure changes directly to registered securities. This ensures that investors relying on those registration statements have consistent, updated information about the ordinary share and ADS framework.

The filing confirms board-level execution through a signature by Motti Farbstein as Chief Executive Officer and Chief Financial Officer on December 23, 2025. Subsequent disclosures in future filings may provide more detail on how the reverse split and ADS ratio change are implemented in the market.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of December 2025

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

The press release attached hereto as Exhibit 99.1 is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On December 23, 2025, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change.” A copy of this press release is furnished herewith as Exhibit 99.1.

1

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated December 23, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 23, 2025	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

3

FAQ

What did Can-Fite BioPharma Ltd. (CANF) report in this 6-K?

Can-Fite BioPharma Ltd. reported that it issued a press release titled “Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change,” dated December 23, 2025.

How does this 6-K affect Can-Fite BioPharma Ltd. (CANF) registration statements?

The company states that the press release is incorporated by reference into its Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872) registration statements.

What corporate actions are mentioned for Can-Fite BioPharma Ltd. (CANF)?

The report refers to a press release announcing a reverse split of its ordinary shares and an ADS ratio change.

When was the related press release by Can-Fite BioPharma Ltd. issued?

The press release titled “Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change” is dated December 23, 2025.

Who signed this Can-Fite BioPharma Ltd. (CANF) report?

The report is signed by Motti Farbstein, who is identified as Chief Executive Officer and Chief Financial Officer.

What type of SEC filing did Can-Fite BioPharma Ltd. submit?

Can-Fite BioPharma Ltd. submitted a Form 6-K, which is a report of a foreign private issuer under the Securities Exchange Act of 1934.